Ozempic and Wegovy: How 2 diabetes medications became the most popular weight-loss drugs

In the United States, nearly three-quarters of adults qualify as overweight or obese, 42% of whom are considered obese. The World Obesity Federation predicts that 51% of the global population will be overweight or obese by 2035. ‘Fast Company’ contributing writer Adam Bluestein joined us to break down how Novo Nordisk, the company behind Ozempic and Wegovy, developed and marketed its weight-loss drugs. He also explained why the drugs have become so popular in the U.S., how drug pricing is extremely complicated and . . . how the medications actually work to help people lose weight. Also, we chatted with Trina Spear about how she founded Figs, a DTC healthcare apparel company.

Om Podcasten

Which companies are on the cutting edge of artificial intelligence? What’s the next major breakthrough in healthcare? How do iconic brands reinvent themselves to appeal to the next generation? Most Innovative Companies is where tech, business, and innovation convene. Join hosts Yasmin Gagne and Josh Christensen as they bring you the latest innovations transforming business and society—and highlights the companies that are reshaping industries and culture.